Alopecia areata market seen reaching $5.72 billion by 2030

The Business Research Company says the global alopecia areata market will grow from $3.81 billion in 2025 to $5.72 billion by 2030, powered by new immunotherapy drugs, teledermatology and more clinical trials. North America led the market in 2025, while Asia-Pacific is expected to grow fastest.

Why it matters: - Alopecia areata treatment is moving from a limited-therapy category toward a broader market shaped by immunology, digital care and personalized medicine. - The projected rise to $5.72 billion by 2030 signals stronger demand for new treatments and services for a condition that can sharply affect quality of life. - Growth in the market also reflects wider attention to autoimmune disease and hair-loss care across clinical and homecare settings.

What happened: - The Business Research Company released its Alopecia Areata Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035. - The report says the alopecia areata market will grow from $3.81 billion in 2025 to $4.11 billion in 2026. - The report projects the market will reach $5.72 billion by 2030, implying a 8.6% compound annual growth rate over the forecast period. - The company published the report from London on Oct. 30, 2026. - A free sample is available here. - The full report is available here.

The details: - Alopecia areata is an autoimmune disorder in which the immune system attacks hair follicles. - The condition causes sudden hair loss in small, smooth scalp patches roughly the size of a coin. - The disease is non-scarring and can affect people of any age. - The historical market growth was driven by rising global prevalence, limited treatment options, growing demand for specialized dermatology services, expanding hospital and clinic infrastructure, and the use of traditional herbal and natural remedies. - The forecast period growth is expected to come from immunotherapy breakthroughs, more funding for dermatology research, a shift toward personalized hair-loss treatment, growth in homecare and teledermatology, and more clinical trials focused on hair regrowth. - The report says increasing alopecia cases are a major market driver, tied to autoimmune disorders, stress, genetic predisposition and environmental factors. - The report cites a July 2023 U.S. Department of Health and Human Services estimate that more than 50 million men and 30 million women in the U.S. are affected by androgenetic alopecia each year. - North America held the largest market share in 2025 because of advanced healthcare infrastructure and strong research activity. - Asia-Pacific is expected to post the fastest growth during the forecast period because of improving healthcare access, rising awareness of autoimmune diseases and expanding dermatology services. - The report also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa.

Between the lines: - The market forecast suggests alopecia areata is becoming more commercially attractive as treatments become more targeted and accessible. - The emphasis on teledermatology and homecare points to a care model that is moving beyond specialist clinics. - The broad regional coverage suggests companies see opportunity not just in established markets, but also in emerging healthcare systems.

What's next: - More clinical trials and immunotherapy development are expected to shape competition in the category. - Wider adoption of personalized treatment and teledermatology could expand patient reach through 2030. - Asia-Pacific may draw more investment as access and awareness improve.

The bottom line: - Alopecia areata is shifting from a niche dermatology segment into a faster-growing global treatment market with room for new drug, digital and service offerings.